Addition of Two New High Cost Specialty Drugs to BIO Case Covered Services

Amondys 45 has been added to the High Cost Specialty Drug case type reinsured services effective 2/25/2021. Amondys 45 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy.

Luxturna has been added to the High Cost Specialty Drug case type reinsured services effective 3/23/2021. Luxturna is a gene therapy indicated for the treatment of patients with Inherited Retinal Disease (IRD) due to the mutations in both copies of the RPE65 gene.

The process for Reinsurance for these drugs will be the same as for other Biological/High Cost Specialty Drugs – see the Reinsurance Manual for details.